201 related articles for article (PubMed ID: 37684239)
21. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
22. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract][Full Text] [Related]
23. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
24. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
25. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
[TBL] [Abstract][Full Text] [Related]
26. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
[TBL] [Abstract][Full Text] [Related]
27. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
28. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
30. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
31. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
[TBL] [Abstract][Full Text] [Related]
32. High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.
Zurowski D; Patel S; Hui D; Ka M; Hernandez C; Love AC; Lin B; Moore A; Chan LL
SLAS Discov; 2023 Apr; 28(3):65-72. PubMed ID: 36758833
[TBL] [Abstract][Full Text] [Related]
33. Preclinical development of CD126 CAR-T cells with broad antitumor activity.
Mishra AK; Kemler I; Dingli D
Blood Cancer J; 2021 Jan; 11(1):3. PubMed ID: 33414408
[TBL] [Abstract][Full Text] [Related]
34. Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy.
He H; Liao Q; Zhao C; Zhu C; Feng M; Liu Z; Jiang L; Zhang L; Ding X; Yuan M; Zhang X; Xu J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615704
[TBL] [Abstract][Full Text] [Related]
35. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
36. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
37. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X
Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635
[TBL] [Abstract][Full Text] [Related]
38. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
39. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
[TBL] [Abstract][Full Text] [Related]
40. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]